{"id":"clm_D79F18FC7528","entity":"regeneron-pharmaceuticals","predicate":"quarterly_operating_income","value":"1,111,000,000 United States dollar","value_json":{"fp":"Q3","fy":2023,"accn":"0001804220-23-000031","form":"10-Q","filed":"2023-11-02","period":"Q3 FY2023","concept":"us-gaap:OperatingIncomeLoss"},"valid_from":"2023-09-30","valid_to":"2024-03-31","published":"2023-11-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Regeneron Pharmaceuticals quarterly operating income: 1,111,000,000 United States dollar\", as of 2023-09-30 (until 2024-03-31). Claim clm_D79F18FC7528, https://asof.is/claim/clm_D79F18FC7528, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422023000031/0001804220-23-000031-index.htm.","url":"https://asof.is/claim/clm_D79F18FC7528","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_5DA47B349189","supersedes":["clm_0742E18258B7"],"first_seen_at":"2026-11-08T17:08:51.481862+00:00","updated_at":"2026-11-08T17:08:58.955536+00:00","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/872589/000180422023000031/0001804220-23-000031-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2023","published_at":"2023-11-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2023, filed 2023-11-02"},"legend":{"dates":"valid_from: when the claim took effect (a period figure: the day its period closed). published: the earliest day a source on the record published it (a filing's filing date, a post's date; null when no source carries one). recorded: the day AsOf first held it. A figure can take effect weeks before it is published.","citation":"citation: how to cite the row (plain: one sentence with the value, its as-of date, the claim id and URL, the day answered and the primary source; url: the claim page; accessed: the day answered). APA and BibTeX forms are on the claim page.","why_not":{},"checked_by":{"sec-filing":"parsed from the SEC filing"}}}